BALA CYNWYD, Pa., April 30, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Gen-Probe Incorporated ("Gen-Probe" or the "Company") (Nasdaq- GPRO) relating to the proposed acquisition by Hologic, Inc. ("Hologic") (Nasdaq-HOLX).

Under the terms of the transaction, Gen-Probe shareholders would receive $82.75 in cash, for each share of Gen-Probe stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Gen-Probe for not acting in the Company's shareholders' best interests in connection with the sale process to Hologic. The transaction may undervalue Gen-Probe as Gen-Probe stock traded at $86.66 as recently as May 18, 2011.

If you own shares of Gen-Probe stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.  You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/417-gpro-gen-probe-incorporated.html, or by calling toll free 877-LEGAL-90.

SOURCE Brodsky & Smith, LLC